Cytori Therapeutics Inc (NASDAQ:CYTX) reported earnings of ($0.19) per share beating Walls Streets expectations.

ME Staff
-
0

Cytori Therapeutics Inc (NASDAQ:CYTX) reported Q2 2017 earnings this Afternoon, coming in at ($0.19) per share, beating Wall Street’s estimates of ($0.21) per Share. Revenue for the quarter came in at $0.90 million missing the streets estimates of $2.23 million

Analyst Coverage For Cytori Therapeutics Inc (NASDAQ:CYTX)
These are 1 Hold Rating, 1 Buy Rating .
The current consensus rating for Cytori Therapeutics Inc (NASDAQ:CYTX) is Buy (Score: 2.50) with a consensus target price of $6.15 , a potential (1,658.65% upside)

Recent Insider Trading for Cytori Therapeutics Inc (NASDAQ:CYTX)

  • On 8/10/2016 John David Harris, VP, bought 2,500 with an average share price of $2.03 per share and the total transaction amounting to $5,075.00.
  • On 6/14/2016 Gail K Naughton, Director, bought 1,000 with an average share price of $2.10 per share and the total transaction amounting to $2,100.00.
  • On 5/13/2016 John David Harris, VP, bought 2,000 with an average share price of $2.71 per share and the total transaction amounting to $5,420.00.
  • On 3/9/2016 David Rickey, Director, bought 150,000 with an average share price of $0.19 per share and the total transaction amounting to $28,500.00.
  • On 9/3/2015 Tommy G Thompson, Director, bought 25,449 with an average share price of $0.37 per share and the total transaction amounting to $9,416.13.
  • On 9/2/2015 Jeremy B Hayden, VP, bought 8,200 with an average share price of $0.36 per share and the total transaction amounting to $2,952.00.



    Recent Trading for Cytori Therapeutics Inc (NASDAQ:CYTX)
    Shares of Cytori Therapeutics Inc closed the previous trading session at 0.350 up +0.010 2.82% with 431,792 shares trading hands.